Inflammatory Bowel Disease Treatment Market Outlook: Growth and Forecast Highlights 2030
Uncover key drivers, emerging technologies, and competitive movements shaping the inflammatory bowel disease treatment market from 2026–2035 with trusted insights from The Business Research Company
Starting from its 2026 valuation, what market size is the Inflammatory Bowel Disease Treatment Market expected to reach by 2030?
The inflammatory bowel disease treatment market size has seen robust expansion in recent years. It is projected to increase from $27.19 billion in 2025 to $29.8 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 9.6%. The market’s past growth can be attributed to factors such as the rising incidence of ulcerative colitis and Crohn’s disease, increased knowledge about IBD treatment alternatives, the expansion of hospital and retail pharmacy infrastructures, the availability of generic aminosalicylates, and the initial embrace of biologics in developed parts of the world.
The inflammatory bowel disease treatment market is projected to experience robust expansion in the coming years, anticipated to reach $43.36 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.8%. This anticipated expansion during the forecast period stems from factors such as enhanced investment in precision medicine, the creation of innovative anti-inflammatory treatments, the incorporation of digital health platforms for patient oversight, a rise in the uptake of biologics and biosimilars, and the broadening of ibd treatment availability in developing regions. Significant developments projected for this timeframe encompass the advancement of personalized ibd therapies, an escalating reliance on biologics in treatment protocols, the emergence of minimally invasive drug delivery methods, a heightened emphasis on patient compliance initiatives, and the proliferation of specialty pharmacies dedicated to ibd.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6704&type=smp
What Drivers Are Driving Adoption Within The Inflammatory Bowel Disease Treatment Market?
The increasing occurrence of Crohn’s disease and ulcerative colitis is a primary force propelling the inflammatory bowel disease treatment market. These conditions, Crohn’s disease and ulcerative colitis, are forms of inflammatory bowel diseases (IBD) that lead to inflammation and sores within the digestive tract. The growing number of cases involving Crohn’s disease and ulcerative colitis is projected to heighten the demand for inflammatory bowel disease treatments, as these are widely utilized to alleviate bowel inflammation and to minimize or prevent associated medical complications. For instance, data from November 2024, according to the Crohn’s & Colitis Foundation, a US-based Non-profit organization, indicates that approximately 100,429 children and adolescents in the United States under 20 years old are affected by IBD, encompassing both Crohn’s disease and ulcerative colitis. Within this pediatric group, Crohn’s disease is more prevalent, showing a rate of 71 per 100,000, in contrast to 44 per 100,000 for ulcerative colitis. Consequently, the rising incidence of Crohn’s disease and ulcerative colitis is anticipated to drive the expansion of the inflammatory bowel disease treatment market.
What Segments Are Included Within The Inflammatory Bowel Disease Treatment Market?
The inflammatory bowel disease treatment market covered in this report is segmented –
1) By Drug Class: Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, Other Drug Classes
2) By Type: Crohn’s Disease, Ulcerative Colitis
3) By Route Of Administration: Oral, Injectable
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Aminosalicylates: Mesalamine, Sulfasalazine, Balsalazide
2) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone
3) By TNF Inhibitors: Infliximab, Adalimumab, Certolizumab pegol
4) By IL Inhibitors: Ustekinumab, Guselkumab
5) By Anti-Integrin: Vedolizumab, Natalizumab
6) By JAK Inhibitors: Tofacitinib, Filgotinib
7) By Other Drug Classes: Antibiotics, Immunosuppressants, Other Novel Therapies
Which Trends Are Expected To Influence The Inflammatory Bowel Disease Treatment Market In The Upcoming Years?
Major companies operating in the inflammatory bowel disease treatment market are developing advanced products, such as therapies for moderate to severe active ulcerative colitis, to cater to larger customer bases, increase sales, and boost revenue. Treatments for moderate to severe active ulcerative colitis typically include medications and sometimes surgical interventions. For instance, in October 2023, Eli Lilly and Company, a US-based pharmaceutical company, announced the U. S. Food and Drug Administration (FDA) approval for Omvoh (mirikizumab-mrkz), which is available in both infusion (300 mg/15 mL) and injection (100 mg/mL) forms, marking it as the inaugural and sole interleukin-23p19 (IL-23p19) antagonist designed to treat adults with moderately to severely active ulcerative colitis (UC). Omvoh is specifically engineered to target the p19 subunit of IL-23, effectively blocking the IL-23 pathway, which is responsible for the inflammation that significantly contributes to the development of UC. The Omvoh treatment regimen initiates with three 300-mg IV infusions, administered once a week every four weeks, before transitioning to a maintenance phase involving two 100-mg subcutaneous self-injections every four weeks.
Who Are The Major Companies Operating In The Inflammatory Bowel Disease Treatment Market?
Major companies operating in the inflammatory bowel disease treatment market are AbbVie Inc., Biogen Inc., Johnson & Johnson, Amgen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Salix Pharmaceuticals Inc., Vifor Pharma AG, Zydus Pharmaceuticals (USA) Inc., Advanced Gastroenterology and Surgery Associates P.A., Atlanta Gastroenterology Associates LLC, Digestive Disease Associates of Rockland P.C., Gastrointestinal Specialists Inc., Illinois Gastroenterology Group LLC, Massachusetts General Hospital, Mayo Clinic, Mount Sinai Health System Inc., The Oregon Clinic – Gastroenterology West P.C.
Access The Complete Report For Deeper Market Insights:
Which Region Is Anticipated To See The Fastest Growth In The Inflammatory Bowel Disease Treatment Market?
North America was the largest region in the inflammatory bowel disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflammatory bowel disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Inflammatory Bowel Disease Treatment Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=6704&type=smp
Browse Through More Reports Similar to the Global Inflammatory Bowel Disease Treatment Market 2026, By The Business Research Company
Inflammatory Bowel Disease Treatment Market Report 2026
Crohns Disease Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/crohns-disease-treatment-global-market-report
Rare Inflammatory Disease Treatment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
